4 recruiting, 2 completed, 2 terminated, 1 active not recruiting. 9 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 4, Completed 2, Terminated 2, Active not recruiting 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Colon Carcinoma: new trials by email Literature Review of Colon Carcinoma trials Research Report on Colon Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment Zanidatamab, Resection, Patient Observation - Colon Carcinoma, Colorectal Carcinoma | Phase 2 | Recruiting | Emory University | 38 | 2026-04-07 | 2026-04-17 |
| Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors Biospecimen Collection, Cannabidiol, Dronabinol - Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy | Phase 2 | Recruiting | City of Hope Medical Center | 120 | 2025-10-03 | 2025-12-05 |
| Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. encorafenib + cetuximab + FOLFIRI - Colorectal Carcinoma, Colorectal Neoplasms | Phase 2 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 25 | 2024-06-03 | 2025-02-12 |
| Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer Acupuncture Therapy, Acupressure Therapy, Oral Cryotherapy - Appendix Carcinoma, Colon Carcinoma | Phase 2 | Completed | University of Washington | 78 | 2021-06-01 | 2026-01-21 |
| Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy Nivolumab - Colon Adenoma, Colon Carcinoma | Phase 2 | Terminated | John Hays | 3 | 2018-10-04 | 2024-07-01 |
| Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer Nivolumab, Ipilimumab, Celecoxib 200mg - Colon Carcinoma | Phase 2 | Recruiting | The Netherlands Cancer Institute | 353 | 2017-03-29 | 2026-09-30 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-11-12 |
| L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases L-BLP25, Placebo - Colon Carcinoma, Rectum Carcinoma | Phase 2 | Completed | Prof. Dr. Carl Schimanski | 122 | 2011-08-01 | 2018-02-13 |
| Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia Inositol, Placebo - Colon Carcinoma, Dysplasia in Crohn Disease | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2010-10-01 | 2016-07-12 |
Colonic Neoplasms (9) · Rectal Neoplasms (5) · Colorectal Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Hepatocellular (2) · Esophageal Neoplasms (2) · Pancreatic Neoplasms (2) · Stomach Neoplasms (2) · Adenoma, Islet Cell (1) · Anus Neoplasms (1) · Appendiceal Neoplasms (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms, Hereditary Nonpolyposis (1) · Endometrial Neoplasms (1) · Gastro-enteropancreatic neuroendocrine tumor (1)
Colonic Diseases (9) · Digestive System Diseases (9) · Digestive System Neoplasms (9) · Gastrointestinal Diseases (9) · Intestinal Diseases (9) · Intestinal Neoplasms (9) · Neoplasms (9) · Neoplasms by Site (9) · Gastrointestinal Neoplasms (8) · Colorectal Neoplasms (6) · Rectal Diseases (6) · Adenocarcinoma (2) · Breast Diseases (2) · Carcinoma (2) · Endocrine Gland Neoplasms (2)
Nivolumab (3) · Specimen Handling (3) · Biopsy (2) · Magnetic Resonance Spectroscopy (2) · X-Rays (2) · relatlimab (2) · 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1) · 2C4 antibody (1) · AZD4547 (1) · Acupressure (1) · Acupuncture Therapy (1) · Ado-Trastuzumab Emtansine (1) · Afatinib (1) · CT-P6 (1) · Cannabidiol (1)
National Cancer Institute (NCI) (2) · City of Hope Medical Center (1) · Emory University (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · John Hays (1) · Prof. Dr. Carl Schimanski (1) · The Netherlands Cancer Institute (1) · University of Washington (1)
United States (6) · Austria (1) · Germany (1) · Guam (1) · Italy (1) · Netherlands (1) · Puerto Rico (1)
Carl Christoph Schimanski, Prof. Dr. (1) · John Hays, MD, Ph.D (1) · Keith T Flaherty (1) · Maria Alessandra Calegari (1) · Myriam Chalabi, MD (1) · Olumide B. Gbolahan, MBBS, MSc (1) · Richard Lee (1) · Seema Khan (1) · Stacey Cohen (1)
PMID 26586415, PMID 32251400, PMID 32463741, PMID 32923171, PMID 33048619, PMID 34606846, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 38838311, PMID 38838316, PMID 39278994, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40865033, PMID 41066729, PMID 41115454
2023 (1), N01CN35157 (1), P30CA015704 (1), P30CA033572 (1), P30CA060553 (1), P30CA138292 (1), U10CA180820 (1), U24CA196172 (1)